These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32169995)

  • 21. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
    Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
    J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PSA screening and deaths from prostate cancer after diagnosis--a population based analysis.
    Wachtel MS; Nelius T; Haynes AL; Dahlbeck S; de Riese W
    Prostate; 2013 Sep; 73(12):1365-9. PubMed ID: 23649537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidence.
    Westerberg M; Beckmann K; Gedeborg R; Irenaeus S; Holmberg L; Garmo H; Stattin P
    J Clin Epidemiol; 2023 Mar; 155():22-30. PubMed ID: 36538980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence of prostate cancer "reverse stage migration" toward more advanced disease at diagnosis: Data from the Pennsylvania Cancer Registry.
    Reese AC; Wessel SR; Fisher SG; Mydlo JH
    Urol Oncol; 2016 Aug; 34(8):335.e21-8. PubMed ID: 27108226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increasing incidence of metastatic prostate cancer in the United States (2004-2013).
    Weiner AB; Matulewicz RS; Eggener SE; Schaeffer EM
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):395-397. PubMed ID: 27431496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in prostate cancer incidence and mortality to monitor control policies in a northeastern Brazilian state.
    Lima CA; da Silva BEB; Hora EC; Lima MS; Brito EAC; Santos MO; da Silva AM; Nunes MAP; Brito HLF; Lima MMM
    PLoS One; 2021; 16(3):e0249009. PubMed ID: 33765051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in prostate cancer incidence and mortality in Croatia, 1988-2008.
    Kulis T; Krhen I; Kastelan Z; Znaor A
    Croat Med J; 2012 Apr; 53(2):109-14. PubMed ID: 22522988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates.
    Feuer EJ; Mariotto A; Merrill R
    Cancer; 2002 Aug; 95(4):870-80. PubMed ID: 12209732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of cases with unknown stage prostate cancer in a population-based cancer registry.
    Luo Q; Yu XQ; Cooke-Yarborough C; Smith DP; O'Connell DL
    Cancer Epidemiol; 2013 Dec; 37(6):813-9. PubMed ID: 24103424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent trends in prostate cancer in Spain.
    Cayuela L; Lendínez-Cano G; Chávez-Conde M; Rodríguez-Domínguez S; Cayuela A
    Actas Urol Esp (Engl Ed); 2020 Sep; 44(7):483-488. PubMed ID: 32600879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer and prostate-specific antigen testing in New South Wales.
    Smith DP; Supramaniam R; Marshall VR; Armstrong BK
    Med J Aust; 2008 Sep; 189(6):315-8. PubMed ID: 18803534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prostate cancer in Cali, Colombia, 1962-2011: incidence, mortality and survival].
    Restrepo JA; Bravo LE; García-Perdomo HA; García LS; Collazos P; Carbonell J
    Salud Publica Mex; 2014; 56(5):440-7. PubMed ID: 25604290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An updated report of the trends in cancer incidence and mortality in Japan.
    Katanoda K; Matsuda T; Matsuda A; Shibata A; Nishino Y; Fujita M; Soda M; Ioka A; Sobue T; Nishimoto H
    Jpn J Clin Oncol; 2013 May; 43(5):492-507. PubMed ID: 23493744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in prostate cancer incidence and mortality in a mid-sized Northeastern Brazilian city.
    Lima CA; Silva AM; Kuwano AY; Rangel MR; Macedo-Lima M
    Rev Assoc Med Bras (1992); 2013; 59(1):15-20. PubMed ID: 23440137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Observational survey on variations of prostate cancer incidence by stage in the Nord-Pas-de-Calais region between 1998 and 2004].
    Flamand V; Zini L; Salleron J; Fantoni JC; Biserte J; Villers A
    Prog Urol; 2008 Jan; 18(1):53-9. PubMed ID: 18342157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
    Kelly SP; Anderson WF; Rosenberg PS; Cook MB
    Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Geospatial and temporal variation of prostate cancer incidence.
    Wah W; Ahern S; Evans S; Millar J; Evans M; Earnest A
    Public Health; 2021 Jan; 190():7-15. PubMed ID: 33321358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in prostate cancer incidence between 1996 and 2013 in two Swiss regions by age, grade, and T-stage.
    Wanner M; Richard A; Matthes K; Ortelli L; Lorez M; Korol D; Bordoni A; Rohrmann S
    Cancer Causes Control; 2018 Feb; 29(2):269-277. PubMed ID: 29204913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.